{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:11:26Z","timestamp":1788783086324,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.08.031","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:31:52Z","timestamp":1787153512000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gemtuzumab Ozogamicin-Containing Salvage Strategies as a Bridge to Second Allogeneic Hematopoietic Stem Cell Transplantation in Post-transplant Relapsed AML"],"prefix":"10.1016","author":[{"given":"Xiao-hong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7964-3181","authenticated-orcid":false,"given":"Jing","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-juan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-huan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-hua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.08.031_bib0001","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3324\/haematol.2022.280798","article-title":"New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia","volume":"108","author":"Mohty","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.08.031_bib0002","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12943-023-01889-6","article-title":"Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy","volume":"22","author":"Sauerer","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtct.2026.08.031_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2023.101466","article-title":"Allogeneic hematopoietic cell transplantation in acute myeloid leukemia","volume":"36","author":"Magee","year":"2023","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jtct.2026.08.031_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.812207","article-title":"Treatment of AML relapse after allo-HCT","volume":"11","author":"Webster","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2026.08.031_bib0005","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood.2024025705","article-title":"How I treat AML relapse after allogeneic HSCT","volume":"145","author":"Gooptu","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.08.031_bib0006","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/bmt.2016.167","article-title":"Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.031_bib0007","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/jcm11010253","article-title":"Prevention and treatment of acute myeloid leukemia relapse after hematopoietic stem cell transplantation: the state of the art and future perspectives","volume":"11","author":"Leotta","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtct.2026.08.031_bib0008","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-021-01148-5","article-title":"Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia","volume":"14","author":"Aitken","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2026.08.031_bib0009","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1038\/s41375-022-01692-0","article-title":"Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis","volume":"36","author":"Short","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.08.031_bib0010","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1182\/bloodadvances.2020002811","article-title":"Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.08.031_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153886","article-title":"Antibody\u2013drug conjugates: a review of approved drugs and their clinical level of evidence","volume":"15","author":"Gogia","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jtct.2026.08.031_bib0012","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-019-0175-x","article-title":"Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia","volume":"7","author":"Yu","year":"2019","journal-title":"Biomark Res"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.031_bib0013","doi-asserted-by":"crossref","first-page":"968.e1","DOI":"10.1016\/j.jtct.2026.05.029","article-title":"Low SOS\/VOD risk with inotuzumab ozogamicin as a bridging strategy to second allogeneic hematopoietic stem cell transplantation: a real-world study in post-transplant relapsed B-ALL","volume":"32","author":"Pan","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.031_bib0014","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2026.08.031_bib0015","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.08.031_bib0016","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/s41409-019-0492-6","article-title":"Validation of treatment outcomes according to revised severity criteria from EBMT for sinusoidal obstruction syndrome\/veno-occlusive disease","volume":"54","author":"Yoon","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.031_bib0017","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.jtct.2026.08.031_bib0018","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International multicenter standardization of acute graft-versus-host disease clinical data collection","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.031_bib0019","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"NIH consensus criteria for clinical trials in chronic graft-versus-host disease: 2014 diagnosis and staging report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.031_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.810387","article-title":"Hypomethylating agent-based combination therapies to treat post-hematopoietic stem cell transplant relapse of acute myeloid leukemia","volume":"11","author":"Ciotti","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2026.08.031_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231154708","article-title":"Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia","volume":"14","author":"Swaminathan","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtct.2026.08.031_bib0022","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/ijms25010484","article-title":"Venetoclax and hypomethylating agent combination in myeloid malignancies: mechanisms of synergy and challenges of resistance","volume":"25","author":"Mishra","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtct.2026.08.031_bib0023","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","article-title":"Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia","volume":"15","author":"Nwosu","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jtct.2026.08.031_bib0024","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.08.031_bib0025","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.08.031_bib0026","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/cancers12010069","article-title":"Immune escape after hematopoietic stem cell transplantation (HSCT): from mechanisms to novel therapies","volume":"12","author":"Bernasconi","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.jtct.2026.08.031_bib0027","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","article-title":"Gemtuzumab ozogamicin for acute myeloid leukemia","volume":"130","author":"Appelbaum","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.08.031_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.08.003","article-title":"Defibrotide shows efficacy in the prevention of sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: a retrospective study","volume":"28","author":"Chalandon","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.031_bib0029","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood-2001-12-0159","article-title":"Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation","volume":"100","author":"Ruutu","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.08.031_bib0030","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/s41409-024-02298-z","article-title":"Total body irradiation versus thiotepa\/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia","volume":"59","author":"Mora","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.031_bib0031","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/leu.2017.187","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia","volume":"31","author":"Godwin","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.08.031_bib0032","first-page":"289","article-title":"Safety and feasibility of physical therapy in cytopenic patients during allogeneic haematopoietic stem cell transplantation","volume":"22","author":"Morishita","year":"2013","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.jtct.2026.08.031_bib0033","series-title":"Principles and Practice of Transplant Infectious Diseases","first-page":"209","article-title":"Infections in allogeneic stem cell transplantation","author":"Pereira","year":"2019"},{"key":"10.1016\/j.jtct.2026.08.031_bib0034","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00277-016-2711-1","article-title":"Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016","volume":"95","author":"Ullmann","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2026.08.031_bib0035","series-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","first-page":"237","article-title":"General management of the patient: specific aspects of infectious disease supportive care in children","author":"Castagnola","year":"2024"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:23:56Z","timestamp":1788780236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726006731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":35,"alternative-id":["S2666636726006731"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.031","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gemtuzumab Ozogamicin-Containing Salvage Strategies as a Bridge to Second Allogeneic Hematopoietic Stem Cell Transplantation in Post-transplant Relapsed AML","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}